BOSTON, Nov. 30, 2005 – CeNeRx raised $18.5 million in a Series A round led by Perseus-Soros. Other investors included L Capital Partners, A.M. Pappas & Associates, and Wistar Morris. CeNeRx is developing reversible inhibitors of monoamine oxidase for depression and anxiety.
Lawrence Wittenberg, partner, and Danielle Lauzon, associate, represented Perseus-Soros in this transaction.